Form 4: Orchestra BioMed Executive William Reed Little Receives Stock Award

William Reed Little, an executive at Orchestra BioMed Holdings, was granted 53,333 restricted stock units (RSUs) on May 8, 2024.

Summary

• William Reed Little, Executive Vice President, Corporate Development & Strategy at Orchestra BioMed Holdings, Inc., received an award of 53,333 restricted stock units (RSUs) on May 8, 2024.
• These RSUs represent a contingent right to receive one share of Common Stock each.
• 8,000 RSUs will vest on May 22, 2025.
• The remaining 45,333 RSUs will vest in equal installments on various dates from August 22, 2025, to May 22, 2028, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice and indicates confidence in the executive's continued contribution to the company.

Positives

• The stock award aligns the executive's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Risks

• The executive's departure before the vesting dates would result in forfeiture of the unvested RSUs.

Industry Context

Stock awards are a common practice in the biotech industry to attract and retain key talent, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock awards for executives in similar-sized biotech companies typically vest over a 3-4 year period, which aligns with the vesting schedule outlined in this Form 4 filing.
• Companies like Medtronic and Boston Scientific also use RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock award positively as it incentivizes the executive to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates